abstract |
This invention is directed to pharmaceutical compositions for treating acute or chronic renal failure or dysfunction, or conditions caused thereby, comprising prostaglandin agonists, which are EP4 receptor selective prostaglandin agonists, in admixture with pharmaceutically acceptable carriers or diluents. |